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1 Despite their high prevalence and deleterious impact on health-related quality of life (HRQoL), depression and anxiety are undertreated in patients with IBD owing to poor recognition and lack of evidence to guide interventions. 2 Acceptance and Commitment Therapy (ACT) is an empirically supported behavioral intervention that integrates acceptance and mindfulness with behavioral change strategies to cultivate psychological flexibility and enhance engagement in meaningful activities. 3, 4 We developed a program consisting of a 1-day (5-hour) ACT plus IBD education (ACT-ED) group workshop for patients with IBD and co-occurring anxiety or depression. A brief workshop was chosen for ease of implementation, and to ensure treatment adherence and completion. 5 The aim of this study was to determine the feasibility of a 1-day ACT-ED workshop in patients with IBD and depression/ anxiety and to examine the preliminary effects on HRQoL, distress, and IBD activity.
Methods
Patients were recruited consecutively from the Michael E. DeBakey VA Medical Center and Baylor College of Medicine. Eligibility criteria were as follows: ages 18 to 75 years, diagnosis of IBD for 3 months or longer, and symptoms of anxiety (General Anxiety Disorder-7 scale 6) or depression (Patient Health Questionnaire 6). 6, 7 Exclusion criteria included schizophrenia or bipolar disorder, current substance abuse, major head injuries, suicidal ideation, and initiation of a medication for anxiety or depression in the preceding 4 weeks. Informed consent was obtained before enrollment.
The ACT-ED workshops were conducted in groups of 6 to 10 participants. Each workshop lasted 5 hours, with 4 hours for teaching and practicing ACT principles and 1 hour for IBD education. All patients received a patient manual, which provided a review and elaborated concepts presented in the ACT-ED workshop.
Outcome assessments were performed at enrollment and at the 3-month follow-up evaluation. The Depression Anxiety and Stress Scale (DASS-21) includes 3 selfreported scales of current depressive, anxiety, and stress symptoms. 8 IBD outcomes were assessed using the Harvey Bradshaw Index for patients with Crohn's disease, and partial Mayo score for patients with ulcerative colitis. HRQoL was assessed using the Short IBD Questionnaire. Changes from baseline to the 3-month follow-up evaluation for all measures were assessed using the paired t test and the Wilcoxon signedrank test.
Results
Sixty-two of 133 screened patients were eligible for enrollment. Of the 62 patients, 29 declined to participate (the most common reason was practical constraints such as time and distance), 12 could not be reached, and 21 patients agreed to participate and were enrolled. One patient who met screening criteria did not meet criteria for enrollment on the day of intervention.
Twenty patients were included in the final analyses (14 men and 6 women; 15 US military veterans). The mean age of the enrolled patients was 51 years (range, 28-73 y), including 9 patients with Crohn's disease, 10 patients with ulcerative colitis, and 1 patient with IBD unclassified. One hundred percent of patients completed the intervention; 2 patients could not be reached for the 3-month assessment.
A total of 79% of the patients showed a decrease in DASS-Anxiety scores from baseline to the 3-month follow-up evaluation, with mean scores decreasing from 6.9 to 4.3 (P < .01) ( Table 1) . DASS-Depression scores showed a numeric improvement from baseline to 3 months in 64% of patients; a trend toward decreased mean depression scores was observed, but was not statistically significant (P ¼ .08). DASS-Stress scores improved in 57% of patients at the 3-month follow-up evaluation; a trend toward decreased mean stress scores was observed but did not reach statistical significance (P ¼ .06). Trends toward improvements in the Short IBD Questionnaire, partial Mayo score, and Harvey Bradshaw Index (P ¼ .08, .28, and .05, respectively) were observed at the 3-month follow-up evaluation, but were not statistically significant. A total of 100% of patients reported a positive experience with the workshop and 95% indicated that they would participate in the ACT-ED workshop again.
Discussion
This study used a 1-day ACT-ED workshop for patients with IBD and co-occurring depression and/or anxiety. This study supports the feasibility and acceptability of an intensive 1-day treatment in this difficult-to-treat patient population. The availability of an effective behavioral intervention that can be completed in 1 day should be considered as an alternative to the regularly prescribed weekly treatments. Implementing a 1-day workshop in a medical setting could provide integrated care for comorbid medical and psychiatric conditions. Despite the small sample size in this study, we showed a statistically significant improvement in anxiety at 3 months. This study provides promising preliminary findings on the effects of ACT-ED on HRQoL, depression, stress, and IBD activity, which merit further study with a larger randomized controlled trial. 
